Jupiter Neurosciences closes IPO on Nasdaq, raises $11M gross from 2.75M shares at $4.00

JUPITER NEUROSCIENCES, INC.

IPO of 2,750,000 common shares priced at $4.00/sh for gross proceeds of $11M.
Net proceeds to Jupiter are approximately $9.5M after underwriting discounts and expenses.
Shares began trading on Nasdaq Capital Market on Dec 3, 2024 under ticker JUNS.
Proceeds earmarked for Phase II trial of JOTROL in Parkinson's, SE Asia initiatives, R&D, license fees, debt repayment, and working capital.
Dominari Securities acted as lead underwriter; Revere Securities as co-manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.